Tempest Therapeutics, Inc. Common Stock
TPSTTempest Therapeutics, Inc. (TPST) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company aims to identify and advance novel immuno-oncology and targeted agents, leveraging a deep understanding of tumor biology to create treatments that improve patient outcomes.
Company News
Tempest Therapeutics has agreed to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, which is expected to extend the company's operational runway to mid-2027 and diversify its clinical-stage pipeline.
Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.
5 hot penny stocks to watch this week. Time to buy now or avoid entirely? The post Penny Stocks To Buy? 5 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
On a day of rising geopolitical tensions, this technical strategist says there are plenty of reasons to be optimistic about stocks
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.
